Table 2.
Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of thiazole compounds 1, 5, 22b–d, 25 and vancomycin against seven methicillin-resistant (MRSA), three vancomycin-intermediate (VISA), and three vancomycin-resistant Staphylococcus aureus (VRSA) strains.
| S. aureus strain | 1 | 5 | 22b | 22c | 22d | 25 | Vancomycin | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||||
| MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | |
| NRS107 (MRSA) |
2.6 | 2.6 | 1.4 | 1.4 | 2.9 | 5.9 | 3.3 | 6.7 | 6.3 | 12.5 | 1.6 | 1.6 | <1.5 | <1.5 |
| NRS119 (MRSA) |
2.6 | 2.6 | 1.4 | 1.4 | 5.9 | 11.7 | 6.7 | 6.7 | 6.3 | 12.5 | 1.6 | 1.6 | <1.5 | <1.5 |
| NRS194 (MRSA) |
1.3 | 1.3 | 1.4 | 1.4 | 5.9 | 11.7 | 6.7 | 13.3 | 6.3 | 6.3 | 1.6 | 1.6 | 0.7 | 0.7 |
| USA300 (MRSA) |
1.3 | 1.3 | 1.4 | 1.4 | 5.9 | 5.9 | 6.7 | 6.7 | 6.3 | 6.3 | 1.6 | 1.6 | 0.7 | 0.7 |
| USA 400 (MRSA) |
1.3 | 1.3 | 1.4 | 1.4 | 5.9 | 11.7 | 6.7 | 13.3 | 6.3 | 6.3 | 1.6 | 1.6 | 0.7 | 0.7 |
| USA500 (MRSA) |
1.3 | 1.3 | 1.4 | 1.4 | 5.9 | 5.9 | 3.3 | 3.3 | 6.3 | 6.3 | 1.6 | 3.2 | 0.7 | 0.7 |
| ATCC 43300 (MRSA) |
1.3 | 1.3 | 1.4 | 1.4 | 5.9 | 5.9 | 3.3 | 3.3 | 6.3 | 6.3 | 1.6 | 1.6 | 0.7 | 0.7 |
| NRS1 (VISA) |
1.3 | 2.6 | 0.7 | 0.7 | 2.9 | 2.9 | 3.3 | 3.3 | 6.3 | 6.3 | 1.6 | 1.6 | 3.0 | 3.0 |
| NRS19 (VISA) |
1.3 | 2.6 | 1.4 | 1.4 | 5.9 | 5.9 | 3.3 | 3.3 | 12.5 | 12.5 | 1.6 | 1.6 | <1.5 | <1.5 |
| NRS37 (VISA) |
2.6 | 2.6 | 1.4 | 1.4 | 2.9 | 5.9 | 3.3 | 3.3 | 3.1 | 6.3 | 1.6 | 1.6 | 3.0 | 3.0 |
| VRS1 (VRSA) |
0.7 | 0.7 | 1.4 | 1.4 | 2.9 | 2.9 | 6.7 | 6.7 | 3.1 | 3.1 | 3.2 | 3.2 | >190.2 | >190.2 |
| VRS4 (VRSA) |
0.7 | 1.3 | 1.4 | 2.8 | 2.9 | 2.9 | 6.7 | 6.7 | 1.6 | 3.1 | 3.2 | 3.2 | >190.2 | >190.2 |
| VRS5 (VRSA) |
0.7 | 1.3 | 2.8 | 2.8 | 2.9 | 2.9 | 6.7 | 6.7 | 6.3 | 6.3 | 3.2 | 3.2 | >190.2 | >190.2 |